„Vincent is a great Finance Leader with a strong focus of the business partner requirements. He works very hard to satisfy the growing demand from the business for Finance to drive performance. He gained business alignment to successfully identify and understand the business strategy and acted as a catalyst in driving forward initiatives critical to delivering the strategy. Vincent provides highly relevant insight into business performance. He is a key stakeholder in the decision making process through the provision of risk-adjusted financial information and analysis. A great asset as a finance business partner and a strong cross-functional team player. Give it to him and things will get done.“
Vincent Lepreux
Metropolregion Lausanne
5009 Follower:innen
500+ Kontakte
5009 Follower:innen
500+ Kontakte
Info
As an Investment Principal at Debiopharm Innovation Fund, the strategic venture capital…
Berufserfahrung
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ausbildung
-
-
-
–
-
-
–
Sprachen
-
French
Muttersprache oder zweisprachig
-
English
Verhandlungssicher
-
German
Grundkenntnisse
Erhaltene Empfehlungen
1 Person hat Vincent Lepreux empfohlen
Jetzt anmelden und ansehenWeitere ähnliche Profile
Weitere Beiträge entdecken
-
David Clark
The VC secondary market is on fire. But many LPs are rushing in without fully appreciating the risks. VenCap International plc has been active in VC secondaries (LP positions only) since 1987 — and this is one of the hottest markets we’ve seen. In the first half of 2025 we reviewed $6.5bn of secondary VC deals — a 41% jump from the $4.6bn we saw in the same period last year. This includes both GP-led and LP-led deals. Here are 4 lessons we've learned from nearly 40 years of buying secondaries: 1️⃣ Power law still rules – a few companies will drive most returns. 2️⃣ Quality over discount – our best deal was bought at a premium to NAV. 3️⃣ Know the valuation policy – different VCs can value the same company very differently. 4️⃣ Factor in manager behavior – holding winners vs. selling early can make or break returns. VC secondaries ≠ PE secondaries. The risks are different — but for LPs who can access the right deal, at the right price, the rewards can be exceptional.
17 Kommentare -
Noubar Afeyan
Flagship Pioneering founded Lila Sciences in 2023 to remake one of the most important human inventions in history: the scientific method. How? By building fully autonomous science labs that enable AI to perform the scientific method itself – from hypothesis to experiment to analysis to iteration. This idea grew out of the internal combination of FL96 and FL97, two earlier Flagship prototyping projects. With FL96 we asked, “What if machines could autonomously reimagine and reconstruct the physical (materials) world?” FL97 wondered, “What if machines could autonomously make life science advances?” Now, Lila is answering those questions. Lila’s AI models don’t just regurgitate existing knowledge when tasked with a research question. They create new knowledge by connecting dots across incumbent scientific literature and traditionally siloed disciplines; generating novel hypotheses; and then designing and conducting experiments to test those hypotheses in our autonomous labs. When this process repeats itself thousands or eventually millions of times in parallel, we believe it will lead to what we call scientific superintelligence — enabling new discoveries on a scale and at a pace that has never been achievable until now. Already, Lila’s team has made early molecular breakthroughs in therapeutics, energy, and carbon capture. At a time when the challenges humanity faces seem to be accelerating, we must also accelerate our ability to find solutions. I believe Lila’s technology has the potential to do that, and to launch a new golden age of science in the process. Today, I’m proud to welcome a new group of investors who have joined Lila’s Series A fundraising round, adding another $235M to the $200M we’ve already raised and bringing the total to $435M. This is an important foundation for Lila’s next phase of discovery and growth. Our work is just beginning. https://lnkd.in/eHGVYaaJ
16 Kommentare -
Dr Fiona Pathiraja-Møller
𝗙𝗲𝗺𝗮𝗹𝗲 𝗳𝗼𝘂𝗻𝗱𝗲𝗿 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗗𝗿 𝗠𝗮𝗿𝗶𝗮 𝗟𝗲𝗶𝗹𝗼𝗴𝗹𝗼𝘂 - 𝘂𝘀𝗶𝗻𝗴 𝘁𝗲𝗰𝗵 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝘁𝗵𝗲 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗮𝘁𝗿𝗲 🏥 Deeptech founder Maria Leiloglou, is using her expertise in biomedical engineering & surgical imaging to develop surgical tech to visualise beyond what the human eye can see 👁️ I'm thrilled to be an investor in EnAcuity, a highly technical spinout from Imperial College London & UCL. EnAcuity specialises in AI-powered medical imaging software which is something I'm particularly passionate about 🤖 Utilising EnAcuity's AI imaging software, surgeons are able view tissues more clearly during laparoscopic surgery, reducing the chances of accidental injuries & improving patient outcomes 🩸 EnAcuity’s software can be used with equipment that’s already found in the operating theatre, making it an easy, sustainable way to improve existing technology ♻️ The team were recently awarded an Innovate UK Smart Grant of £300,840 to roll their software out in hospitals across the UK 🇬🇧 Just 2p of every £1 invested in venture capital funding in the UK goes to female-founded businesses, with female Deeptech founders receiving even less 💸 If we want future technologies to be developed in a more equitable way, we need women in STEM (Science, Tech, Engineering, Maths) to build companies based on their unique perspectives & experiences 👩🏽🔬👩🏽⚕️ 𝗔𝗻𝗱 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗲𝗺𝗮𝗹𝗲 𝗳𝗼𝘂𝗻𝗱𝗲𝗿𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲𝘆 𝗻𝗲𝗲𝗱 💰 -- ♻ Re-share if this resonated with you. 👩🏽⚕️Follow Dr Fiona Pathiraja-Møller for more.
16 Kommentare